[Safety of specific cyclo-oxygenase 2 inhibitors].
Swaak
A J
AJ
Theunissen
D J
DJ
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000068579:Celecoxib; D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000191:economics; D004359:Drug Therapy, Combination; D005756:Gastritis / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D000077239:Meloxicam; D009426:Netherlands; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones; D013843:Thiazines / Q000009:adverse effects; D013844:Thiazoles / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; D013843:Thiazines; D013844:Thiazoles; C116926:rofecoxib; D000068579:Celecoxib; D000077239:Meloxicam